Optimal use of L‐asparaginase (NSC‐109229) in acute lymphocytic leukemia

Barbara Jones; James F. Holland; Oliver Glidewell; Claude Jacquillat; Marise Weil; Carl Pochedly; Lucius Sinks; Louise Chevalier; Harold M. Maurer; Kjell Koch; Geoffrey Falkson; Richard Patterson; Barbara Seligman; Jurg Sartorius; Faith Kung; Farid Haurani; Marie Stuart; E. Omer Burgert; Frederick Ruymann; Arthur Sawitsky; Edwin Forman; Hansjuerg Pluess; John Truman; Nasrollah Hakami

doi:10.1002/mpo.2950030410

Optimal use of L‐asparaginase (NSC‐109229) in acute lymphocytic leukemia

Barbara Jones, James F. Holland, Oliver Glidewell, Claude Jacquillat, Marise Weil, Carl Pochedly, Lucius Sinks, Louise Chevalier, Harold M. Maurer, Kjell Koch, Geoffrey Falkson, Richard Patterson, Barbara Seligman, Jurg Sartorius, Faith Kung, Farid Haurani, Marie Stuart, E. Omer Burgert, Frederick Ruymann, Arthur SawitskyEdwin Forman, Hansjuerg Pluess, John Truman, Nasrollah Hakami

Pediatrics Hematology/Oncology

Research output: Contribution to journal › Article

69 Scopus citations

Abstract

Between 1971 and 1974, 646 evaluable patients under 20 years of age with previously untreated acute lymphocytic leukemia were treated according to Cancer and Leukemia Group B (formerly Acute Leukemia Group B) Protocol 7111. On a random basis, they received a 10‐day course of 1,000 units/kg/day of L‐asparaginase before, during, or after a 3‐week course of vincristine and corticosteroid. A control group received vincristine and corticosteroid for 4 weeks but no asparaginase. The overall complete remission rate was 85%, which was not altered significantly by any of the induction variables. Patients who received asparaginase for 10 days subsequent to vincristine and corticosteroid had a significantly longer complete remission duration with an estimated median of 45 months, compared to 20 months for the group receiving no asparaginase and 27 months for the other 2 asparaginase regimens. The beneficial effect of asparaginase was noted, irrespective of which 1 of the 2 intensification and maintenance programs the patients received. The 5‐year projection indicates a complete remission rate of 50% for those patients receiving subsequent asparaginase as compared to 41% of those induced on other regimens in this study and thus is superior to the use of only vincristine and corticosteroid.

Original language	English (US)
Pages (from-to)	387-400
Number of pages	14
Journal	Medical and Pediatric Oncology
Volume	3
Issue number	4
DOIs	https://doi.org/10.1002/mpo.2950030410
State	Published - 1977

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Oncology
Cancer Research

Access to Document

10.1002/mpo.2950030410

Fingerprint Dive into the research topics of 'Optimal use of L‐asparaginase (NSC‐109229) in acute lymphocytic leukemia'. Together they form a unique fingerprint.

Cite this

Jones, B., Holland, J. F., Glidewell, O., Jacquillat, C., Weil, M., Pochedly, C., Sinks, L., Chevalier, L., Maurer, H. M., Koch, K., Falkson, G., Patterson, R., Seligman, B., Sartorius, J., Kung, F., Haurani, F., Stuart, M., Burgert, E. O., Ruymann, F., ... Hakami, N. (1977). Optimal use of L‐asparaginase (NSC‐109229) in acute lymphocytic leukemia. Medical and Pediatric Oncology, 3(4), 387-400. https://doi.org/10.1002/mpo.2950030410

Optimal use of L‐asparaginase (NSC‐109229) in acute lymphocytic leukemia. / Jones, Barbara; Holland, James F.; Glidewell, Oliver; Jacquillat, Claude; Weil, Marise; Pochedly, Carl; Sinks, Lucius; Chevalier, Louise; Maurer, Harold M.; Koch, Kjell; Falkson, Geoffrey; Patterson, Richard; Seligman, Barbara; Sartorius, Jurg; Kung, Faith; Haurani, Farid; Stuart, Marie; Burgert, E. Omer; Ruymann, Frederick; Sawitsky, Arthur; Forman, Edwin; Pluess, Hansjuerg; Truman, John; Hakami, Nasrollah.

In: Medical and Pediatric Oncology, Vol. 3, No. 4, 1977, p. 387-400.

Research output: Contribution to journal › Article

Jones, B, Holland, JF, Glidewell, O, Jacquillat, C, Weil, M, Pochedly, C, Sinks, L, Chevalier, L, Maurer, HM, Koch, K, Falkson, G, Patterson, R, Seligman, B, Sartorius, J, Kung, F, Haurani, F, Stuart, M, Burgert, EO, Ruymann, F, Sawitsky, A, Forman, E, Pluess, H, Truman, J & Hakami, N 1977, 'Optimal use of L‐asparaginase (NSC‐109229) in acute lymphocytic leukemia', Medical and Pediatric Oncology, vol. 3, no. 4, pp. 387-400. https://doi.org/10.1002/mpo.2950030410

Jones, Barbara ; Holland, James F. ; Glidewell, Oliver ; Jacquillat, Claude ; Weil, Marise ; Pochedly, Carl ; Sinks, Lucius ; Chevalier, Louise ; Maurer, Harold M. ; Koch, Kjell ; Falkson, Geoffrey ; Patterson, Richard ; Seligman, Barbara ; Sartorius, Jurg ; Kung, Faith ; Haurani, Farid ; Stuart, Marie ; Burgert, E. Omer ; Ruymann, Frederick ; Sawitsky, Arthur ; Forman, Edwin ; Pluess, Hansjuerg ; Truman, John ; Hakami, Nasrollah. / Optimal use of L‐asparaginase (NSC‐109229) in acute lymphocytic leukemia. In: Medical and Pediatric Oncology. 1977 ; Vol. 3, No. 4. pp. 387-400.

@article{fb6d515aebc94485b163e14c956e03b5,

title = "Optimal use of L‐asparaginase (NSC‐109229) in acute lymphocytic leukemia",

abstract = "Between 1971 and 1974, 646 evaluable patients under 20 years of age with previously untreated acute lymphocytic leukemia were treated according to Cancer and Leukemia Group B (formerly Acute Leukemia Group B) Protocol 7111. On a random basis, they received a 10‐day course of 1,000 units/kg/day of L‐asparaginase before, during, or after a 3‐week course of vincristine and corticosteroid. A control group received vincristine and corticosteroid for 4 weeks but no asparaginase. The overall complete remission rate was 85%, which was not altered significantly by any of the induction variables. Patients who received asparaginase for 10 days subsequent to vincristine and corticosteroid had a significantly longer complete remission duration with an estimated median of 45 months, compared to 20 months for the group receiving no asparaginase and 27 months for the other 2 asparaginase regimens. The beneficial effect of asparaginase was noted, irrespective of which 1 of the 2 intensification and maintenance programs the patients received. The 5‐year projection indicates a complete remission rate of 50% for those patients receiving subsequent asparaginase as compared to 41% of those induced on other regimens in this study and thus is superior to the use of only vincristine and corticosteroid.",

author = "Barbara Jones and Holland, {James F.} and Oliver Glidewell and Claude Jacquillat and Marise Weil and Carl Pochedly and Lucius Sinks and Louise Chevalier and Maurer, {Harold M.} and Kjell Koch and Geoffrey Falkson and Richard Patterson and Barbara Seligman and Jurg Sartorius and Faith Kung and Farid Haurani and Marie Stuart and Burgert, {E. Omer} and Frederick Ruymann and Arthur Sawitsky and Edwin Forman and Hansjuerg Pluess and John Truman and Nasrollah Hakami",

year = "1977",

doi = "10.1002/mpo.2950030410",

language = "English (US)",

volume = "3",

pages = "387--400",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "4",

}

TY - JOUR

T1 - Optimal use of L‐asparaginase (NSC‐109229) in acute lymphocytic leukemia

AU - Jones, Barbara

AU - Holland, James F.

AU - Glidewell, Oliver

AU - Jacquillat, Claude

AU - Weil, Marise

AU - Pochedly, Carl

AU - Sinks, Lucius

AU - Chevalier, Louise

AU - Maurer, Harold M.

AU - Koch, Kjell

AU - Falkson, Geoffrey

AU - Patterson, Richard

AU - Seligman, Barbara

AU - Sartorius, Jurg

AU - Kung, Faith

AU - Haurani, Farid

AU - Stuart, Marie

AU - Burgert, E. Omer

AU - Ruymann, Frederick

AU - Sawitsky, Arthur

AU - Forman, Edwin

AU - Pluess, Hansjuerg

AU - Truman, John

AU - Hakami, Nasrollah

PY - 1977

Y1 - 1977

N2 - Between 1971 and 1974, 646 evaluable patients under 20 years of age with previously untreated acute lymphocytic leukemia were treated according to Cancer and Leukemia Group B (formerly Acute Leukemia Group B) Protocol 7111. On a random basis, they received a 10‐day course of 1,000 units/kg/day of L‐asparaginase before, during, or after a 3‐week course of vincristine and corticosteroid. A control group received vincristine and corticosteroid for 4 weeks but no asparaginase. The overall complete remission rate was 85%, which was not altered significantly by any of the induction variables. Patients who received asparaginase for 10 days subsequent to vincristine and corticosteroid had a significantly longer complete remission duration with an estimated median of 45 months, compared to 20 months for the group receiving no asparaginase and 27 months for the other 2 asparaginase regimens. The beneficial effect of asparaginase was noted, irrespective of which 1 of the 2 intensification and maintenance programs the patients received. The 5‐year projection indicates a complete remission rate of 50% for those patients receiving subsequent asparaginase as compared to 41% of those induced on other regimens in this study and thus is superior to the use of only vincristine and corticosteroid.

AB - Between 1971 and 1974, 646 evaluable patients under 20 years of age with previously untreated acute lymphocytic leukemia were treated according to Cancer and Leukemia Group B (formerly Acute Leukemia Group B) Protocol 7111. On a random basis, they received a 10‐day course of 1,000 units/kg/day of L‐asparaginase before, during, or after a 3‐week course of vincristine and corticosteroid. A control group received vincristine and corticosteroid for 4 weeks but no asparaginase. The overall complete remission rate was 85%, which was not altered significantly by any of the induction variables. Patients who received asparaginase for 10 days subsequent to vincristine and corticosteroid had a significantly longer complete remission duration with an estimated median of 45 months, compared to 20 months for the group receiving no asparaginase and 27 months for the other 2 asparaginase regimens. The beneficial effect of asparaginase was noted, irrespective of which 1 of the 2 intensification and maintenance programs the patients received. The 5‐year projection indicates a complete remission rate of 50% for those patients receiving subsequent asparaginase as compared to 41% of those induced on other regimens in this study and thus is superior to the use of only vincristine and corticosteroid.

UR - http://www.scopus.com/inward/record.url?scp=0017662049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017662049&partnerID=8YFLogxK

U2 - 10.1002/mpo.2950030410

DO - 10.1002/mpo.2950030410

M3 - Article

C2 - 337095

AN - SCOPUS:0017662049

VL - 3

SP - 387

EP - 400

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 4

ER -